

Prior failed ipsilateral percutaneous endovascular intervention in patients with critical limb ischemia predicts poor outcome after lower extremity bypass

Brian W. Nolan, MD, MS,^a Randall R. De Martino, MD,^a David H. Stone, MD,^a Andres Schanzer, MD,^b Philip P. Goodney, MD, MS,^a Daniel W. Walsh, MD,^a and Jack L. Cronenwett, MD,^a for the Vascular Study Group of New England, Lebanon, NH; and Worcester, Mass

Background: Although open surgical bypass remains the standard revascularization strategy for patients with critical limb ischemia (CLI), many centers now perform peripheral endovascular intervention (PVI) as the first-line treatment for these patients. We sought to determine the effect of a prior ipsilateral PVI (iPVI) on the outcome of subsequent lower extremity bypass (LEB) in patients with CLI.

Methods: A retrospective cohort analysis of all patients undergoing infrainguinal LEB between 2003 and 2009 within hospitals comprising the Vascular Study Group of New England (VSGNE) was performed. Primary study endpoints were major amputation and graft occlusion at 1 year postoperatively. Secondary outcomes included in-hospital major adverse events (MAE), 1-year mortality, and composite 1-year major adverse limb events (MALE). Event rates were determined using life table analyses and comparisons were performed using the log-rank test. Multivariate predictors were determined using a Cox proportional hazards model with multilevel hierarchical adjustment.

Results: Of 1880 LEBs performed, 32% (n = 603) had a prior infrainguinal revascularization procedure (iPVI, 7%; ipsilateral bypass, 15%; contralateral PVI, 3%; contralateral bypass, 17%). Patients with prior iPVI, compared with those without a prior iPVI, were more likely to be women (32 vs 41%; $P = .04$), less likely to have tissue loss (52% vs 63%; $P = .02$), more likely to require arm vein conduit (16% vs 5%; $P = .001$), and more likely to be on statin (71% vs 54%; $P = .01$) and beta blocker therapy (92% vs 81%; $P = .01$) at the time of their bypass procedure. Other demographic factors were similar between these groups. Prior PVI or bypass did not alter 30-day MAE and 1-year mortality after the index bypass. In contrast, 1-year major amputation and 1-year graft occlusion rates were significantly higher in patients who had prior iPVI than those without (31% vs 20%; $P = .046$ and 28% vs 18%; $P = .009$), similar to patients who had a prior ipsilateral bypass (1 year major amputation, 29% vs 20%; $P = .022$; 1 year graft occlusion, 33% vs 18%; $P = .001$). Independent multivariate predictors of higher 1-year amputation and graft occlusion rates were prior iPVI, prior ipsilateral bypass, dialysis dependence, prosthetic conduit and distal (tibial and pedal) bypass target.

Conclusions: Prior iPVI is highly predictive for poor outcome in patients undergoing LEB for CLI with higher 1-year amputation and graft occlusion rates than those without prior revascularization, similar to prior ipsilateral bypass. These findings provide information, which may help with the complex decisions surrounding revascularization options in patients with CLI. (J Vasc Surg 2011;54:730-6.)

Although open surgical bypass provides the most durable option for limb salvage in patients with critical limb ischemia (CLI),¹ it has substantial morbidity and mortality. Thus, many centers prefer to initially treat CLI patients with a less-invasive endovascular peripheral en-

dovascular intervention (PVI) instead of open bypass. Results of the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial suggest that overall differences in amputation-free survival (AFS) after PVI vs bypass are insignificant.^{2,3}

Although the potential benefit of less-invasive PVI is clear, the potential negative impact of PVI on ultimate limb salvage in CLI patients is unclear. In the BASIL Trial, patients undergoing bypass after a failed PVI had worse AFS than those undergoing primary bypass.^{3,4} Additionally, previous studies have suggested that patients who failed PVI and went on to require bypass needed longer bypasses to more distal targets.^{5,6} These findings have stimulated debate over PVI vs bypass as the optimal first-line strategy for the treatment of CLI.

The outcome of secondary lower extremity bypass after failed primary bypass is known to be poor, with significantly higher graft occlusion and amputation rates.^{7,8} However, the outcome of lower extremity bypass after failed ipsilat-

From the Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon^a; and the Section of Vascular Surgery, University of Massachusetts, Memorial Medical Center, Worcester.^b

Competition of interest: none.

Additional material for this article may be found online at www.jvascsurg.org. Presented at the 2010 Vascular Annual Meeting of the Society for Vascular Surgery, June 10-13, 2010, Boston, Mass.

Reprint requests: Brian W. Nolan, MD, MS, Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, 3V Lebanon, NH, 03766 (e-mail: brian.w.nolan@hitchcock.org).

The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a competition of interest.

0741-5214/\$36.00

Copyright © 2011 by the Society for Vascular Surgery.

doi:10.1016/j.jvs.2011.03.236

eral PVI (iPVI) is not established. The purpose of this study is to assess the effect of a failed prior PVI on the outcome of infrainguinal bypass performed for CLI and to compare the magnitude of this effect with the impact of a failed previous bypass graft.

METHODS

Study design, sample, and database. This is a retrospective cohort analysis of 1880 infrainguinal bypass grafts performed between January 2003 and December 2009 for CLI (rest pain or tissue loss) in 10 centers participating in the Vascular Study Group of New England (VSGNE). The VSGNE is a regional cooperative quality improvement initiative developed by community and academic centers in 2002 to study regional outcomes in vascular surgery. Further details on this registry have been published previously⁹ and are available at <http://www.vsgne.org>. In the VSGNE registry, we collect over 70 preoperative, intraoperative, and postoperative variables, as well as key outcomes at 1-year follow-up, as described in previous publications.^{9,10}

Historical information collected at the time of surgery indicated that 32% ($n = 603$) of patients had undergone an infrainguinal revascularization procedure at some time prior to the index bypass procedure being entered into the VSGNE registry. These consisted of 7% ($n = 132$) iPVI, 15% ($n = 275$) ipsilateral bypass, 3% ($n = 62$) contralateral PVI, and 17% ($n = 326$) contralateral bypass. One hundred ninety-four patients (10%) underwent multiple revascularization procedures. These are shown in the Appendix (online only). The number of patients undergoing bypass with a history of a prior ipsilateral PVI varied substantially among centers, ranging from 2% to 13% (data not shown) and the observed variation was used to adjust for outcomes in our statistical modeling. Details of these previous procedures were not further recorded, so timing and precise type of previous bypass or PVI is not known.

Study endpoints. To evaluate the outcomes of lower extremity bypass (LEB) following a failed PVI, we chose our study endpoints to target safety and efficacy of the procedure as previously described.¹¹ The principal efficacy outcomes of this study were major amputation (above or below knee) and graft occlusion within the first year postoperatively to evaluate efficacy of LEB. The safety outcomes included in-hospital major adverse events (myocardial infarction, congestive heart failure, dysrhythmia requiring treatment, wound infection, renal insufficiency, respiratory failure, pneumonia, graft infection, return to the operating room, death, graft occlusion, or major amputation). Additional efficacy outcomes included 1-year mortality and 1-year major adverse limb events (major adverse limb events [MALE] – major above-knee amputation, new bypass, jump graft/interposition graft, graft occlusion or major reintervention requiring thrombectomy or thrombolysis).¹¹

Definitions of patient medical comorbidities in the VSGNE have been defined elsewhere.¹² These include chronic obstructive pulmonary disease (COPD; chart history), congestive heart failure (CHF; chart history or doc-

umented ejection fraction $<50\%$ on preoperative testing), coronary artery disease (CAD; any history of angina, myocardial infarction [MI], prior coronary intervention, or electrocardiogram [EKG] changes consistent with previous MI), chronic renal insufficiency (CRI; $\text{Cr} \geq 1.8 \text{ mg/dL}$), end-stage renal disease (ESRD; on dialysis), diabetes mellitus (DM; chart history, designated as diet-controlled, on oral hypoglycemic agents, or on insulin), and hypertension (HTN; chart history or blood pressure $\geq 140/90$), hyperlipidemia (HLIP; chart history). For our analysis, distal bypass included tibial and pedal targets.

Analysis. Demographic data were compared using a t test for continuous variables and χ^2 with Fischer exact correction for categorical or dichotomous variables. Rates were determined using Kaplan–Meier life table analyses. Comparisons of rates were made using the log-rank test. Multivariate predictors of major amputation and graft occlusion were determined using Cox proportional hazards models. Univariate predictors for outcomes identified in Table I were tested in our multivariate model and those that were significant were included in the multivariate model, including graft type and target vessel. Multilevel (hierarchical) modeling was performed to account for differences in outcomes across centers. All analyses were performed using Microsoft Excel (Redmond, Wash) and Stata (College Station, Tex). The Institutional Review Board at Dartmouth Medical School approved the analysis of de-identified data from our registry for this study.

RESULTS

Most demographic factors were similar when compared between those who underwent prior iPVI and those who did not (Table I). However, patients who had been treated with prior iPVI were less likely to have tissue loss, were more likely to be women, were more likely to be on statin therapy and beta blocker therapy at the time of their index bypass, and were more likely to require arm vein for conduit ($P < .05$). Although there was a tendency for these patients to require more distal, tibial bypass targets, this finding was not statistically significant and their subsequent outcome was not changes.

Overall, in-hospital major adverse events occurred in 27% of patients after bypass for CLI in VSGNE with no prior revascularization procedures. This event rate was not affected by whether or not a patient had undergone previous iPVI or bypass (Table II). Similarly, 1-year mortality (12%) was not different among these groups (Table II).

Major amputation by 1 year postoperatively, however, was significantly more likely after infrainguinal bypass if patients had a prior iPVI, at 31% ($P = .046$), or prior bypass, at 29% ($P = .022$), compared with 20% in patients without prior revascularization procedures (Fig 1). Prior contralateral procedures (PVI or bypass) were not associated with a higher rate of amputation (Fig 1). Similarly, the 1-year graft occlusion rate was significantly higher in patients who had prior iPVI, at 28% ($P = .009$), or prior bypass at 33% ($P < .001$), compared with only 18% in patients without prior ipsilateral revascularization (Fig 2).

Table I. Patient characteristics

	No prior revasc ^a (n=1277)	Ipsilateral PVI (n=134)	Bypass (n=275)	Contralateral PVI (n=62)	Bypass (n=326)
Age	70	68	68	67	70
Male	68%	59% ^b	64%	65%	70%
Tobacco use	80%	82%	88% ^b	84%	82%
Hypertension	86%	90%	89%	95%	94% ^b
Diabetes	56%	58%	57%	66% ^b	68% ^b
CAD	40%	42%	47% ^b	47%	44%
CHF	23%	24%	16% ^b	19%	21%
COPD	31%	34%	34%	39%	29%
Dialysis	10%	5% ^b	5% ^b	15%	9%
Renal insufficiency	20%	13%	12% ^b	17%	19%
Tissue loss	63%	52% ^b	49% ^b	53%	63%
Pre-op beta blocker	81%	92% ^b	84%	94% ^b	88%
ASA	68%	73%	66%	76%	69%
Statin	54%	71% ^b	59%	69% ^b	61% ^b
Prosthetic conduit	24%	29%	46% ^b	39% ^b	32% ^b
Arm vein conduit	5%	16% ^b	17% ^b	11% ^b	15% ^b
Crural distal target	47%	53%	54%	29% ^b	49%

ASA, Aspirin; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; PVI, peripheral vascular intervention.

Renal insufficiency defines as creatinine >1.8. Coronary artery disease (CAD), congestive heart failure (CHF), and chronic obstructive pulmonary disease (COPD) defined by chart history.

^aRevasc, revascularization procedure (PVI or bypass).

^bP < .05 (compared with no prior revascularization group).

Table II. Major adverse events (MAE) and 1-year mortality based on prior revascularization

Type of prior revascularization	In hospital MAE	P ^a	One-year mortality (P value ^b)	P ^b
No prior revascularization ^a	27%		12%	
Ipsilateral				
Prior PVI	30%	.54	13%	.95
Prior bypass	28%	.83	13%	.51
Contralateral				
Prior PVI	34%	.22	13%	.85
Prior bypass	35%	.54	12%	.36

PVI, Peripheral vascular intervention.

Major adverse events include myocardial infection, congestive heart failure, dysrhythmia requiring treatment, wound infection, renal insufficiency, respiratory failure, pneumonia, graft infection, return to the operating room, death, graft occlusion, or major amputation.

^aComparison by χ^2 statistic.

^bComparison by log-rank statistic.

As a combined endpoint, MALE were significantly more likely in patients with prior iPVI, or bypass (Fig 3).

By multivariate analysis, predictors of 1-year major amputation rate were prior ipsilateral PVI or bypass, dialysis dependence, prosthetic conduit, and tibial level bypass target. Aspirin was found to be protective. Prior ipsilateral PVI or bypass similarly increased the risk of major amputation by approximately 50% in addition to dialysis dependence, prosthetic conduit, and tibial level target. Aspirin use was protective of amputation at 1 year (Table III). Finally, prior ipsilateral PVI and bypass also increased the risk of 1-year graft occlusion by 50% (Table IV). Dialysis dependence, prosthetic conduit, arm vein conduit, a tibial




Fig 1. One-year major amputation rates in patients undergoing lower extremity bypass who have undergone prior revascularization procedure. P values compared with patients with no prior revascularization procedure. PVI, Peripheral vascular intervention.

level bypass target, and female gender also increased the risk of graft occlusion by multivariate analysis (Table IV).

DISCUSSION

Our study shows that a prior ipsilateral infrainguinal PVI is an important predictor of poor outcomes after lower extremity bypass for CLI. According to multivariate analysis, a prior iPVI increased both the risk of limb loss and the risk of occlusion of a subsequent infrainguinal bypass by approximately 50% at 1 year. This magnitude of effect was very similar to the negative predictive effect of a prior ipsilateral bypass that has reported patency rates of only 50% to 60% and limb salvage rates of 80% at 1 year.¹³ Other factors identified in our risk-prediction model have been previously reported to confer a negative effect on lower extremity bypass outcomes.




Fig 2. One-year graft occlusion rates in patients undergoing lower extremity bypass who have undergone prior revascularization procedure. *P* values compared with patients with no prior revascularization procedure. *PVI*, Peripheral vascular intervention.

These factors include dialysis dependence, prosthetic conduit, tibial (as opposed to popliteal) target and female gender,¹⁴⁻¹⁶ lending face validity to the risk prediction model. Aspirin was found to be protective as previously noted by others.¹⁷ These findings lend support to the general applicability of the VSGNE findings. In contrast to the impact of prior ipsilateral PVI or bypass, contralateral PVI or bypass did not affect the risk of either amputation or graft occlusion. Thus, systemic factors such as a hypercoagulable state are less likely to have been responsible for the negative impact of a prior ipsilateral procedure. Further, there were no differences in postoperative major adverse events or 1-year mortality between patients having primary bypass vs those who had prior ipsilateral revascularization, suggesting that prior ipsilateral revascularization primarily impacts graft-related events, rather than global patient-related outcomes such as medical, graft, or wound complications.

The BASIL trial is the only large-scale randomized control trial to evaluate the outcomes of PVI vs bypass in patients eligible for both. The results of our study regarding the impact of prior PVI on AFS are similar to those published in the BASIL Trial,³ which reported AFS at 1 year of only 40% for bypass after failed angioplasty vs 70% after initial bypass. Though not an endpoint of our study, corresponding 1-year results for AFS in VSGNE were 53% for bypass after failed angioplasty vs 76% after initial bypass ($P = .03$), very similar to the BASIL results.

The outcomes of prior failed PVI have been described in other studies,^{4-6,18} but few evaluate the impact of the PVI on subsequent bypass, as most are treated with a repeat PVI.^{6,18} In a review of failed PVI, five of 46 patients with failed PVI required subsequent bypass with a 20% amputation rate. Similarly, of 39 early (<30 day) PVI failures, Galaria et al reported that 19 required subsequent bypass with a similar 17% rate of amputation.¹⁸ In a study of 25 bypasses after failed PVI, Böckler et al demonstrated similar outcomes to the present study with a bypass failure rate of 50% and an amputation rate of 44% over a median of 6 months.⁴

The effect of a failed PVI on a distal anastomotic site is less well understood. Joels et al reported that a failed PVI resulted in a more distal target for bypass in 28% of cases and half of these patients had compromised runoff as a result of PVI failure.⁵ Conversely, others have reported the opposite. One study of 46 failed PVIs reported no change in distal anastomosis site over a mean follow-up of 8.7 months.⁶ Another reported that of 39 PVI failures, there was no change in distal anastomotic site. This discrepancy in the literature may be due to the small number of cases in each study where a failed PVI required a subsequent bypass. While the present study is the largest to date to report on bypass outcome after a prior PVI, we are unable to determine if the PVI failure affected the distal target since information of the index procedure is not tracked in our database.

Why is prior ipsilateral PVI or bypass associated with worse results for infrainguinal bypass? Several possible explanations exist. First, failure of prior PVI or bypass could be a surrogate for patient-specific risk factors such as hypercoagulability¹⁵ that are not measured in our registry. However, this seems unlikely given that a previous failed contralateral revascularization procedure was not associated with any negative effects. Second, a prior failed PVI or bypass could compromise runoff for a future bypass by embolization or thrombosis. While this has been demonstrated in previous reports,⁵ we were only able to identify a trend ($P = .15$) in this cohort for secondary bypasses to require a more distal target artery than primary bypasses. Finally, marginal vein quality may have dictated the initial choice of PVI or the type of previous bypass (for example, initial use of prosthetic graft if vein quality was marginal). If marginal vein was then resorted to for the subsequent bypass, this could negatively influence graft outcome.¹⁹ Vein quality used for bypass is not recorded in our registry beyond the use of arm vein or spliced veins, which were included in our analyses. In our multivariate models, arm vein was significantly associated with graft occlusion at 1 year but not with major amputation.

Our study has several limitations. Most notably, we know only that patients in our registry had undergone a prior bypass or PVI, but we do not have data on the type of procedure or when it occurred. Others reporting on similar complications after PVI note that patients with failure present within 4 to 6 months after their procedure.^{4,5} Additionally, we do not have data on the total number of PVI procedures previously performed, which might provide a better understanding of the association between a failed PVI and later bypass. The VSGNE is now tracking all PVIs prospectively to assist in answering these questions. Finally, without a randomized trial, the effect of unknown confounders exists. Yet, we have attempted to minimize the effect of this with sound statistical methods in our multivariate model and adjust for potential confounders such as differences across centers or distal target vessels. When controlling for all of these known factors, a prior PVI still appears to be associated with a risk of major graft events at 1 year.




Fig 3. Freedom from major adverse limb events after lower extremity bypass. Major adverse limb event includes amputation, graft occlusion, or reintervention. *PVI*, Peripheral vascular intervention.

Table III. Independent predictors of major amputation at 1 year

	HR	95% CI	
Dialysis	2.7	2.2	3.3
Prosthetic conduit	2.1	1.3	3.4
Prior ipsilateral PVI	1.5	1.1	2
Prior ipsilateral bypass	1.4	1.1	1.7
Tibial target	1.4	1.2	1.7
Aspirin	0.8	0.7	0.9

CI, Confidence interval; HR, hazard ratio; PVI, peripheral vascular intervention.

Table IV. Independent predictors of graft occlusion at 1 year

	HR	95% CI	
Tibial target	1.9	1.6	2.4
Dialysis	1.8	1.3	2.5
Arm vein conduit	1.7	1.3	2.1
Prosthetic conduit	1.6	1.3	1.8
Prior ipsilateral PVI	1.5	1.1	2.1
Prior ipsilateral bypass	1.4	1.2	1.6
Female gender	1.3	1.1	1.5

CI, Confidence interval; HR, hazard ratio; PVI, peripheral vascular intervention.

In conclusion, while it is well known that a prior failed ipsilateral infrainguinal bypass is a negative predictor for future LEB success, this study demonstrates that a prior failed infrainguinal ipsilateral PVI has a similar negative prognostic effect on subsequent LEB. While we are unable to definitively prove causation, prior failed ipsilateral PVI is associated with 1-year major amputation or graft occlusion in the same manner that other established factors such as dialysis dependence, synthetic conduit and distal target arteries are. While some patients may benefit from an initial PVI, those who are eligible for either procedure may benefit from bypass given our findings and those of the BASIL trial. Further work is necessary to clarify the durability, utility, and

cost-effectiveness of a PVI-first approach for patients presenting with CLI.

AUTHOR CONTRIBUTIONS

Conception and design: BN, DS, AS, PG, JC
 Analysis and interpretation: BN, DS, PG, DW, LC
 Data collection: BN, AS, PG, JC
 Writing the article: BN, RD
 Critical revision of the article: BN, RD, JC
 Final approval of the article: BN, LC
 Statistical analysis: BN, PG
 Obtained funding: JC
 Overall responsibility: BN

REFERENCES

- Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. *J Vasc Surg* 2010;51:230-41.
- Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FG, Gillespie I, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. *J Vasc Surg* 2010;51:15S-17S.
- Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FG, Gillespie I, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: analysis of amputation free and overall survival by treatment received. *J Vasc Surg* 2010;51:18S-31S.
- Böckler D, Blaurock P, Mansmann U, Schwarzbach M, Seelos R, Schumacher H, et al. Early surgical outcome after failed primary stenting for lower limb occlusive disease. *J Endovasc Ther* 2005;12:13-21.
- Joels CS, York JW, Kalbaugh CA, Cull DL, Langan EM III, Taylor SM, et al. Surgical implications of early failed endovascular intervention of the superficial femoral artery. *J Vasc Surg* 2008;47:562-5.
- Ryer EJ, Trocciola SM, DeRubertis B, Lam R, Hynecsek RL, Karwowski J, et al. Analysis of outcomes following failed endovascular treatment of chronic limb ischemia. *Ann Vasc Surg* 2006;20:440-6.
- Rossi PJ, Skelly CL, Meyerson SL, Bassiouny HS, Katz D, Schwartz LB, et al. Redo infrainguinal bypass: factors predicting patency and limb salvage. *Ann Vasc Surg* 2003;17:492-502.
- Biancari F, Railo M, Lundin J, Albäck A, Kantonen I, Lehtola A, et al. Redo bypass surgery to the infrapopliteal arteries for critical leg ischaemia. *Eur J Vasc Endovasc Surg* 2001;21:137-42.
- Cronenwett JL, Likosky DS, Russell MT, Eldrup-Jorgensen J, Stanley AC, Nolan BW. A regional registry for quality assurance and improvement: the Vascular Study Group of Northern New England (VSGNNE). *J Vasc Surg* 2007;46:1093-101; Discussion:101-2.
- Bertges DJ, Goodney PP, Zhao Y, Schanzer A, Nolan BW, Likosky DS, et al. The Vascular Study Group of New England Cardiac Risk Index

- (VSG-CRI) predicts cardiac complications more accurately than the Revised Cardiac Risk Index in vascular surgery patients. *J Vasc Surg* 2010;52:674-83, 683. e1-83. e3.
11. Conte MS, Geraghty PJ, Bradbury AW, Hevelone ND, Lipsitz SR, Moneta GL, et al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. *J Vasc Surg* 2009;50:1462-73 e1-3.
 12. Cronenwett JL, Likosky DS, Russell MT, Eldrup-Jorgensen J, Stanley AC, Nolan BW. A regional registry for quality assurance and improvement: the Vascular Study Group of Northern New England (VSGNNE). *J Vasc* 2007;46:1093-101; discussion 101-2.
 13. Belkin M, Conte MS, Donaldson MC, Mannick JA, Whittemore AD. Preferred strategies for secondary infrainguinal bypass: lessons learned from 300 consecutive reoperations. *J Vasc Surg* 1995;21:282-93; discussion:93-5.
 14. Singh N, Sidawy AN, DeZee KJ, Neville RF, Akbari C, Henderson W. Factors associated with early failure of infrainguinal lower extremity arterial bypass. *J Vasc Surg* 2008;47:556-61.
 15. Giswold ME, Landry GJ, Sexton GJ, Yeager RA, Edwards JM, Taylor LM Jr, et al. Modifiable patient factors are associated with reverse vein

graft occlusion in the era of duplex scan surveillance. *J Vasc Surg* 2003;37:47-53.

16. Nguyen LL, Hevelone N, Rogers SO, Bandyk DF, Clowes AW, Moneta GL, et al. Disparity in outcomes of surgical revascularization for limb salvage: race and gender are synergistic determinants of vein graft failure and limb loss. *Circulation* 2009;119:123-30.
17. Collins TC, Soucek J, Beyth RJ. Benefits of antithrombotic therapy after infrainguinal bypass grafting: a meta-analysis. *Am J Med* 2004; 117:93-9.
18. Galaria, SSM, II, Rhodes JM, Shortell CK, Illig KA, Davies MG. Implications of early failure of superficial femoral artery endoluminal interventions. *Ann Vasc Surg* 2005;19:787-92.
19. Donaldson MC, Mannick JA, Whittemore AD. Causes of primary graft failure after in situ saphenous vein bypass grafting. *J Vasc Surg* 1992; 15:113-8; discussion:8-20.

Submitted Dec 8, 2010; accepted Mar 8, 2011.

Additional material for this article may be found online at www.jvascsurg.org.

DISCUSSION

Dr Hasan Dosluoglu (Buffalo, NY). Two quick questions. Did you have the data that differentiated between arterectomies as prior endovascular interventions versus others as contributing factors? And the second one, were prior endovascular interventions performed by vascular surgeons or other specialties and did it have an impact?

Dr Brian W. Nolan. Unfortunately, we do not have any information about the prior interventions. We simply know whether they had a prior intervention or a prior bypass. We do not know what type of intervention, be it atherectomy, angioplasty, stent, or anything else. And, we do not know who did those procedures or when. So unfortunately, while that would be very interesting and potentially useful, I do not have the answer to your question.

Dr John Jeb Hallett (Charleston, SC). Based upon the experience you have had in New England, we are forming a vascular study group in the Carolinas now. And the question comes up: Once you have this information, how are you using it in the study group to try to tighten up the variability that you demonstrated in peripheral interventions?

Dr Nolan. One of the focuses of our study group is to examine variability and the sources of variability. We are also, of course, interested in developing quality improvement measures we can employ to better the care of our patients. As far as what we do with the results of this study, first, it is probably most important for counseling our patients: Is PVI a free shot? Well, maybe not. Because whether or not a patient has a PVI first or a bypass, it looks like the outcome with the subsequent procedure is the same. Second, we have recently started a PVI database, so we will now collect the types of information that may help us answer some of the more complex questions about which types of interventions are more or less successful.

Dr Paul Bloch (Portland, Me). One thing that you showed is very interesting: Namely that bypass following endovascular intervention is at higher risk for failure. You showed something that we already knew, which is that a second bypass after a previous bypass is at a higher risk for failure than the first one. Interestingly, it appears that in this study, a second bypass after a prior failed bypass had a higher failure rate than a bypass after a prior failed endovascular intervention. Were those numbers significant?

Dr Nolan. No. In fact, there was no significant difference between. Actually, they are very similar. They both seem, in our analysis, to increase the risk of amputation, occlusion, or major adverse limb events by about 50%. And amputation was a little bit higher for PVI, but occlusion is a little higher for bypass. I think, for me, overall, the take-home is that they are actually very similar.

Dr Michael Silane (New York, NY). You must have had many other patients who had previous PVIs or bypasses that did very well. So aren't you selecting your worst patients and therefore they are going to have worse results than the patients who have not had a previous PVI or procedure?

Dr Nolan. That is a very good point. We do not know the denominator, so to speak. Certainly, in the study group, we do not, at this point, record all of our PVIs. As I mentioned, it is part of a new initiative. There has been plenty of successes with PVIs, and we are really just looking at bypass after a failed PVI and how a failed PVI predicts the outcome of a future bypass. So in a sense, you are right, we do not know all the people who were treated successfully with PVI. But for this study, we really were just concerned with the impact of a failed PVI on bypass.

Dr Christos Liapis (Athens, Greece). Do you have any information regarding the timing of the two operations? I mean, if it was immediately after a failed endovascular procedure or if it was a late event, like a couple of years later?

Dr Nolan. Unfortunately, we do not. I did not show the data form, maybe that would have been helpful, but essentially, it is simple checkbox data entry. We know the patient had a prior ipsilateral PVI, infrainguinal ipsilateral PVI, contralateral infrainguinal PVI, ipsilateral suprainguinal, contralateral suprainguinal. We do not know the type of intervention, timing of intervention, who did it, where, or anything else, we just know that they had an intervention.

Dr Maciej Dryjski (Buffalo, NY). I would like to congratulate you. This is a very important message you delivered. It is the first time it has been so clearly presented that when we perform endovascular intervention, we burn bridges for successful future bypasses. We still do not understand the reason for that, however, it is most likely a result of embolization. We have recently found that distal TcPO₂ decreases during, and immediately after, endovascular intervention on SFA and popliteal arteries. We do not see any significant clinical markers for embolization because it probably affects medium-size arteries in the pedal arch.

Dr Nolan. Thank you for your comments.

Dr George Andros (Van Nuys, Calif). For years, it seems that the venous papers attracted the greatest number of discussants, so I am pleased to see so many speakers for an arterial paper. Your manuscript raises questions about outcomes that need to be asked and answered. I would just limit my question to the simple question of patency: We know when, as Chris Liapis suggested, an arterial bypass occludes. You palpate it and it does not pulsate. All too often, we do not know when a peripheral intervention occludes, sometimes the patient do not get a foot pulse and we lack a clinical indicator for what is patency. Other than restoration of a

lumen as seen on angiography how did you decide that the PTA was successful and then how did you decide it was failed?

Dr Nolan. That is a good point. And it could be that maybe I misspoke in saying “failed.” All we know is that they had a prior procedure. And I guess, by definition, if they needed a bypass after having an intervention, then we would assume that the interven-

tion did not do what it was intended to do. But we do not actually have any hemodynamic information. It is possible that some patients, for example, had an SFA stent, but they still had tibial disease. The SFA stent was doing just fine, but they required a more distal bypass. And we do not know specifically that it failed, only that they had a prior procedure.